Epstein-Barr virus vaccine by 2032?
RegulierungOne-OffGesundheit & MedizinChinaEuropaKriminalität & Justiz5J
Manifold MarketsKein KYCVerifizierte AuflösungsdatenGut kalibriertAktuelle Community-PrognoseNein 65.3%
Prognostiker
5
Fragetyp
binary
Methodik
Play-money forecasting platform
Quellentyp
Prognose
Marktdaten
Aktualisiert vor 18 Stunden
Veraltet26. Okt. 25, 19:27 UTC31. Dez. 31, 23:59 UTC
Trends
Regeln
Resolution: YES if, by 00:00 UTC on Jan 1, 2032, at least one prophylactic EBV vaccine (an active immunization product) has received regulatory authorization for use to prevent EBV infection or EBV‑associated disease (e.g., infectious mononucleosis, post‑transplant lymphoproliferative disease) from any of the following: FDA (U.S.), EMA (EU), MHRA (U.K.), PMDA (Japan), NMPA (China), Health Canada, TGA (Australia), or if the product appears on the WHO Emergency Use Listing (EUL) or the WHO prequalification (PQ) list for EBV prevention.
- What counts:
- Prophylactic EBV vaccines intended to prevent infection and/or clinical disease (e.g., Moderna’s mRNA‑1189; ferritin‑nanoparticle vaccines; other platforms).
- Approvals may be for specific age/risk groups or limited indications (e.g., prevention of mono in adolescents, or prevention of EBV disease in transplant recipients).
- Any formal regulatory approval/authorization meeting the above criteria counts.
- What doesn’t count:
